|
1
|
Lewis LD: Cancer therapeutics revisited;
novel drugs targeting cell signalling pathways, genome wide
association studies and other trials and tribulations. Br J Clin
Pharmacol. 76:317–319. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sliwkowski MX and Mellman I: Antibody
therapeutics in cancer. Science. 341:1192–1198. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Snook AE and Waldman SA: Advances in
cancer immunotherapy. Discov Med. 15:120–125. 2013.PubMed/NCBI
|
|
4
|
Workman P, Al-Lazikani B and Clarke PA:
Genome-based cancer therapeutics: targets, kinase drug resistance
and future strategies for precision oncology. Curr Opin Pharmacol.
13:486–496. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Waldmann TA: Immunotherapy: past, present
and future. Nat Med. 9:269–277. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bonaccorsi I, Pezzino G, Morandi B and
Ferlazzo G: Novel perspectives on dendritic cell-based
immunotherapy of cancer. Immunol Lett. 155:6–10. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rodel F, Hoffmann J, Distel L, et al:
Survivin as a radioresistance factor, and prognostic and
therapeutic target for radiotherapy in rectal cancer. Cancer Res.
65:4881–4887. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Su L, Wang Y, Xiao M, Lin Y and Yu L:
Up-regulation of survivin in oral squamous cell carcinoma
correlates with poor prognosis and chemoresistance. Oral Surg Oral
Med Oral Pathol Oral Radiol Endod. 110:484–491. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang M, Latham DE, Delaney MA and
Chakravarti A: Survivin mediates resistance to antiandrogen therapy
in prostate cancer. Oncogene. 24:2474–2482. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Uchida H, Tanaka T, Sasaki K, et al:
Adenovirus-mediated transfer of siRNA against survivin induced
apoptosis and attenuated tumor cell growth in vitro and in vivo.
Mol Ther. 10:162–171. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kikkawa K, Fujii R, Kuramoto T, et al:
Dendritic cells with transduced survivin gene induce specific
cytotoxic T lymphocytes in human urologic cancer cell lines.
Urology. 74:222–228. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schmitz M, Diestelkoetter P, Weigle B, et
al: Generation of survivin-specific CD8+ T effector
cells by dendritic cells pulsed with protein or selected peptides.
Cancer Res. 60:4845–4849. 2000.PubMed/NCBI
|
|
14
|
Dauer M, Obermaier B, Herten J, et al:
Mature dendritic cells derived from human monocytes within 48 h: a
novel strategy for dendritic cell differentiation from blood
precursors. J Immunol. 170:4069–4076. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xie Z, Chen Y, Li Z, et al: Smad6 promotes
neuronal differentiation in the intermediate zone of the dorsal
neural tube by inhibition of the Wnt/beta-catenin pathway. Proc
Natl Acad Sci USA. 108:12119–12124. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dauer M, Obermaier B, Herten J, et al:
Mature dendritic cells derived from human monocytes within 48
hours: a novel strategy for dendritic cell differentiation from
blood precursors. J Immunol. 170:4069–4076. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ziegler-Heitbrock L: The CD14+ CD16+ blood
monocytes: their role in infection and inflammation. J Leukoc Biol.
81:584–592. 2007. View Article : Google Scholar
|
|
18
|
Abdi K, Singh NJ and Matzinger P:
Lipopolysaccharide-activated dendritic cells: “exhausted” or alert
and waiting? J Immunol. 188:5981–5989. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mukherjee S, Maiti PK and Nandi D: Role of
CD80, CD86, and CTLA4 on mouse CD4(+) T lymphocytes in enhancing
cell-cycle progression and survival after activation with PMA and
ionomycin. J Leukoc Biol. 72:921–931. 2002.PubMed/NCBI
|
|
20
|
O’Neill DW, Adams S and Bhardwaj N:
Manipulating dendritic cell biology for the active immunotherapy of
cancer. Blood. 104:2235–2246. 2004. View Article : Google Scholar
|
|
21
|
Zhong H, Shurin MR and Han B: Optimizing
dendritic cell-based immunotherapy for cancer. Expert Rev Vaccines.
6:333–345. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shurin MR: Preparation of human dendritic
cells for tumor vaccination. Method Mol Biol. 215:437–462.
2003.
|
|
23
|
Jeras M, Bergant M and Repnik U: In vitro
preparation and functional assessment of human monocyte-derived
dendritic cells-potential antigen-specific modulators of in vivo
immune responses. Transpl Immunol. 14:231–244. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
McIlroy D and Gregoire M: Optimizing
dendritic cell-based anticancer immunotherapy: maturation state
does have clinical impact. Cancer Immunol Immunother. 52:583–591.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li F, Ambrosini G, Chu EY, et al: Control
of apoptosis and mitotic spindle checkpoint by survivin. Nature.
396:580–584. 1998. View
Article : Google Scholar : PubMed/NCBI
|
